Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
… ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results LEIDEN, The Netherlands & … financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… to childhood blindness and has no available treatment options. In the trial, QR-110 demonstrated rapid and … investigator Artur Cideciyan, Ph.D., research professor of ophthalmology at the Scheie Eye Institute, University of … analysis are encouraging and met our decision criteria to stop enrollment in this study and progress to a pivotal Phase …
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st
… Meeting of the Association for Research in Vision and Ophthalmology (ARVO) the company presented pre-clinical data … LCA 10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, … QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow® is a …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… Company’s novel RNA editing technologies Presented at the European Cystic Fibrosis Society (ECFS) conference on … Eluforsen is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… announced several presentations highlighting the Company’s proprietary Axiomer ® RNA editing technology platform at … the 8 th annual Oligonucleotide and Precision Therapeutics (OPT) Congress, March 13-14, 2023 in Boston, MA, U.S.; RNA …